Virtual Library
Start Your Search
S. Lee
Author of
-
+
P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.04-036 - The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas (ID 2210)
09:30 - 09:30 | Author(s): S. Lee
- Abstract
Background:
The prognostic role of epidermal growth factor receptor (EGFR) mutations in patients with lung adenocarcinomas remains controversial and the association between EGFR mutations and stage at the time of the initial diagnosis is debatable. Here we evaluated the association of EGFR mutations with initial stage in lung adenocarcinomas.
Methods:
From June 2011 to December 2014, 1004 consecutive patients who were diagnosed with lung adenocarcinomas and tested for EGFR mutations were retrospectively analyzed. As screening detects lung cancer at early stage, screening was incorporated as a confounder in multivariable analysis.
Results:
Among 1004 patients with lung adenocarcinomas, EGFR mutations were detected in 49.2% (494 of 1004). In multivariable analysis, EGFR mutations were significantly associated with early stage (stage I to II) at diagnosis (OR, 0.65; 95% CI, 0.49 to 0.87; P = 0.003). When adjusted for age, sex, smoking status, and screening, adjusted proportion of EGFR mutations significantly decreased according to stage. Adjusted proportion of EGFR was 57.6% (95% CI, 51.7% to 63.3%) in stage I, 47.9% (95% CI, 36.9% to 59.0%) in stage II, 47.5% (95% CI, 39.6% to 55.5%) in stage III, and 43.4% (95% CI, 38.3% to 48.6%) in stage IV (P = 0.0082).
Conclusion:
The presence of EGFR mutations is significantly associated with early stage at initial diagnosis in lung adenocarcinomas after adjusting for age, sex, smoking status, and screening. This finding implies that EGFR mutations may play a role as a positive prognostic marker.
